Amycretin is an investigational molecule developed by Novo Nordisk that acts on two receptors involved in appetite and blood-sugar signaling - the GLP-1 receptor and the amylin receptor - within a single compound. It has been studied in early clinical trials in both oral and injectable forms.

What is amycretin's regulatory status, and can you buy it?

It is not FDA-approved and is not available for human use. Amycretin is an investigational compound in early-phase clinical trials, and its safety and efficacy in people have not been established.

How is amycretin different from semaglutide?

Semaglutide is a GLP-1 receptor agonist and is the molecule in approved prescription drugs. Amycretin is a different, unapproved compound that adds amylin receptor activity to GLP-1 activity in one molecule, and it is being explored in both oral and injectable forms. The two are studied for overlapping metabolic endpoints, but amycretin remains investigational.

What did amycretin's early trials report?

Early Phase 1b/2a research reported reductions in body weight over the study period, with an average figure of roughly 22% reported in one early injectable cohort. These are early-stage, small-sample findings reported in the trial, not confirmed outcomes, and larger and longer studies are still needed.

← All peptides

Peptide data sheet

Amycretin

GLP-1 · NNC0487-0111 · NN0487

Verdict

promising

for metabolic and weight-related research endpoints

By MrPepTalks Editorial

Reviewed for scientific accuracy · research information, not medical advice

Last updated Jul 8, 2026Reviewed Jul 8, 2026

Quick answer

Amycretin is an investigational molecule from Novo Nordisk that activates two appetite-signaling pathways at once - the GLP-1 receptor and the amylin receptor - in a single compound available in early trials as both a tablet and an injection. It is commonly discussed for weight-related and metabolic endpoints, but it remains in early clinical study, is not FDA-approved, and is not available for human use.

At a glance

Class: Unimolecular GLP-1 receptor and amylin receptor dual agonist (investigational)
Half-life: Reported as supporting once-weekly injectable and once-daily oral schedules in early trials
FDA status: Not FDA-approved; investigational, in early-phase clinical trials only

Which form actually works?

Injectable (subcutaneous, once-weekly)

Promising

The injectable form is the more-studied route in early trials; researchers reported meaningful reductions in body weight over the study window, but the data comes from small, short, early-phase cohorts.

Oral (tablet)

Promising

An oral peptide that survives the gut is unusual and part of why amycretin drew attention; the oral form is studied for the same metabolic endpoints, though human data is even more limited than the injectable.

Read the full Amycretin verdictThe deep-dive: every study and Pep's honest take.Reconstitution calculatorConcentration and draw-volume math — informational only.

Third-Party Testing & Certificate of Analysis (COA)

A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.

HPLC — purity: High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
Mass spectrometry (MS) — identity: Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.

It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.

New to reading one? This guide walks through a COA line by line: how to read a peptide COA.

Sources

Related peptides

All GLP-1 →

Cagrilintidepromising Retatrutidepromising Tirzepatidepromising

Frequently asked questions

Send it to me →

No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.